Toronto, Canada – June 23, 2025 – Altis Labs, Inc. (“Altis”), the computational imaging company accelerating clinical trials with AI, today announces that is has entered into a collaboration agreement with Johnson & Johnson Innovative Medicine.

Trained on the industry’s most comprehensive multimodal real-world dataset, Altis’ AI models will support the evaluation of novel outcome measures that have the potential to accelerate trial timelines, reduce costs, and improve evidence generation in drug development.

This collaboration reflects our commitment to accelerating clinical development with state-of-the-art AI.

‍